Single-cell RNA sequencing in endometrial cancer: exploring the epithelial cells and the microenvironment landscape

Front Immunol. 2024 Aug 20:15:1425212. doi: 10.3389/fimmu.2024.1425212. eCollection 2024.

Abstract

Single-cell RNA sequencing (scRNA-seq) technology has emerged as a powerful tool for dissecting cellular heterogeneity and understanding the intricate biology of diseases, including cancer. Endometrial cancer (EC) stands out as the most prevalent gynecological malignancy in Europe and the second most diagnosed worldwide, yet its cellular complexity remains poorly understood. In this review, we explore the contributions of scRNA-seq studies to shed light on the tumor cells and cellular landscape of EC. We discuss the diverse tumoral and microenvironmental populations identified through scRNA-seq, highlighting the implications for understanding disease progression. Furthermore, we address potential limitations inherent in scRNA-seq studies, such as technical biases and sample size constraints, emphasizing the need for larger-scale research encompassing a broader spectrum of EC histological subtypes. Notably, a significant proportion of scRNA-seq analyses have focused on primary endometrioid carcinoma tumors, underscoring the need to incorporate additional histological and aggressive types to comprehensively capture the heterogeneity of EC. By critically evaluating the current state of scRNA-seq research in EC, this review underscores the importance of advancing towards more comprehensive studies to accelerate our understanding of this complex disease.

Keywords: cellular heterogeneity; endometrial cancer; immune landscape; single-cell RNA sequencing; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Animals
  • Biomarkers, Tumor / genetics
  • Endometrial Neoplasms* / genetics
  • Endometrial Neoplasms* / pathology
  • Epithelial Cells / metabolism
  • Epithelial Cells / pathology
  • Female
  • Humans
  • Sequence Analysis, RNA
  • Single-Cell Analysis* / methods
  • Tumor Microenvironment* / genetics

Substances

  • Biomarkers, Tumor

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This review was funded by grants from the Instituto de Salud Carlos III (PMP22/00054, PI22/01892, PMP21/00107). “A way to achieve Europe” (FEDER) and by the Spanish Association Against Cancer Scientific Foundation (AECC) (Grupos Coordinados Traslacionales AECC 2018).